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Current guidelines advise to maintain immunomodulators and biologicals in pregnant patients because
relapse of inflammatory bowel is associated with unfavourable pregnancy outcome. With the exception
of Methotrexate, IBD therapy seems not to be related to an increase of congenital malformations or
infections requiring hospitalisation of the babies, although the effect the on the developing immune
system of the exposed infants remains unknown. In this review we will focus on the effect of IBD drugs
on health-related outcomes in children taking into account possible long-term effects of biologicals and
immunomodulators, which are transferred across the placenta.
© 2019 Elsevier Ltd. All rights reserved.Introduction
Pre-conception counselling women with inflammatory bowel
disease (IBD) is challenging but extremely important. Many women
with IBD are afraid that IBD might lead to complications during
pregnancy or immunosuppressive medication might harm the
neonate [1]. Voluntary childlessness is increased in women with
IBD and is associated with lack of knowledge of how IBD and
immunosuppressive medication might influence the outcome of
pregnancy and the neonate [2,3]. Women who receive pre-
conception counselling are less likely to be voluntarily childless
[3]. Relapse of IBD has been associated with unfavourable preg-
nancy outcomes with an increased risk of spontaneous abortion,
prematurity and low birth weight [4,5]. Therefore current guide-
lines advise to maintain IBD drugs such as immunomodulators and
biologicals during pregnancy [6,7]. Most IBD drugs are consideredWieringa), c.vanderwoude@
er Woude CJ, Effect of biologi
bowel disease, Best Practof low risk during pregnancy, since no increase of congenital mal-
formations has been reported so far [8e10]. However the effects on
the developing immune system of infants, especially of those drugs
transferred across the placenta remain uncertain as published co-
horts are mostly small and retrospective.Anti-Tumor Necrosis Factor alpha therapy
Anti-Tumor Necrosis Factor alpha (anti TNFa) inhibits the bio-
logical function of the pro-inflammatory cytokine TNFa by
neutralization of soluble and membrane bound TNFa. Several
different TNFa inhibitors have been shown to be effective in IBD
and are currently used: Infliximab, Adalimumab and golimumab
are all monoclonal (IgG1) immunoglobulins blocking TNFa,
whereas certolizumab is a pegylated Fab-fragment binding TNFa
[11,12].
Like other maternal immunoglobulins anti TNFa drugs are
transferred across the placenta passively in low amounts
throughout pregnancy [12]. Nearly all anti -TNFa drugs also have
the ability to actively pass the placenta during the second half ofcals and JAK inhibitors during pregnancy on health-related outcomes
ice & Research Clinical Gastroenterology, https://doi.org/10.1016/
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results in high concentrations of anti- TNFa in the neonate, some-
times exceeding the maternal concentration by a factor 2 at birth
[12e15]. Intrauterine exposure extends beyond the neonatal period
because of the long half-life of this biological in infants, which is at
least twice as long as in adults [16]. Anti- TNFa can still be detected
in the child 12 months after birth [16,17]. Certolizumab pegol does
not bind the neonatal Fc receptor and concentrations of certolizu-
mab are very low or undetectable in cord blood [18,19].
Most safety data about the effect of intra uterine exposure are
from studies with adalimumab and infliximab. Data on golimumab
are scarce [20,21]. A recent case report did however describe
maternal-fetal transfer of golimumab resulting in golimumab
concentration (with last dose given 4 days before birth) in the
neonate of 8 mg/ml (121% ofmaternal concentration) [20]. Given the
mechanism of action the effect of intra uterine exposure to goli-
mumabmight be comparable to adalimumab and infliximab. Long-
term effects of exposure to certolizumab are probably less likely
since certolizumab concentrations are very low or undetectable in
cord blood.
Risk of congenital malformations and unfavourable neonatal
pregnancy outcome
Intra uterine exposure of infants to anti TNFa has not been
associated with adverse pregnancy outcomes such as spontaneous
abortions premature birth, low birth weight or congenital malfor-
mations [8e10,22,23].
Anti TNFa and the developing immune system
Concerns might be raised about the effect of anti TNFa on the
developing immune system of the exposed children. Anti TNFa
drugs might have a direct effect on the immune system during
pregnancy but also on the developing immune system after birth.
TNFa has been shown to be important in the development of the
immune system in mice. Mice with a TNFa deficiency show an
increased susceptibility to infection, reduced delayed hypersensi-
tivity response and a decreased humoral immune response.
Although immunoglobulin class switch does occur in these mice,
they have a deregulated humoral response to antigens, exemplified
by a lack of splenic primary B cell follicles and follicular dendritic
cells [24]. TNFa also regulates growth and functional activities of
normal T cells and is able to induce the formation of regulatory T-
cells. Hypothetically anti-TNFa could have an effect on the devel-
oping immune system in humans as well, although TNFa is not
completely absent after intra uterine exposure.
Recently a study of T and B cell subsets in children, in utero
exposed to infliximab or adalimumabmonotherapy (n¼ 11), or to a
combination of thiopurines with either adalimumab or infliximab
(n ¼ 4) was published. Children of mothers with IBD, exposed to
certolizumab pegol monotherapy (n ¼ 4) were considered refer-
ence population. In children exposed to combination therapy a
trend toward reduction in three B cell subsets and lower frequency
of certain T cells was seen [25]. It was suggested that the reduction
in B cell subsets were an effect of combination therapy rather than
purely anti-TNFa since TNF- deficient mice did not exhibit a
reduction of plasmablasts or memory B cells. Statistical significance
was not reached, but numbers were small.
Extensive immunological tests in another small study have
shown a decreased response after mycobacterial challenge, a more
immature B and T helper phenotype and a decreased regulatory T
cell frequency [26].
Neutropenia has been described in adults using anti-TNFa
therapy [27] as well as in infants after intra uterine exposurePlease cite this article as: Wieringa JW, van der Woude CJ, Effect of biologi
in children of women with inflammatory bowel disease, Best Pract
j.bpg.2019.101665[26,28]. In a small case series 4 newborns with in utero exposure to
anti-TNFa were reported with severe neutropenia and subsequent
development of skin infections (n ¼ 3) and Enterobacter cloacae
diarrhea (n ¼ 1). Treatment of the infants consisted of granulocyte-
colony stimulating factor (G-CSF) and antibiotics. Neutropenia
resolved within the first year of life [28]. In the previously
mentioned small study [26] neutrophil counts below the reference
range in the cord blood of two out of six neonates exposed to anti-
TNFawere found. One of themwas also exposed to steroids and the
other was exposed to anti-TNFa and azathioprine. A severe neu-
tropenia at 3 months of age in one and moderate neutropenia in
two out of six patients was observed. None of them suffered of skin
infections [26].
Vaccination of children after exposure to anti- TNFa therapy
Currently it is advised to avoid live attenuated vaccines (i.e. BCG,
measles-mumps, rubella MMR) until the levels of anti-TNFa are
undetectable [7,29], as there has been one report of an infant, who
died after a Bacillus-Calmette- Guerin (BCG) vaccination associated
with exposure to anti-TNFa in utero [30].
Besides safety issues, the effectiveness of vaccination in children
exposed to anti-TNFa have has also been questioned. Studies in
adults with IBD using immunosuppressive drugs have shown that
the response to 23-valent pneumococcal vaccine is decreased
[31e33]. The response to conjugated pneumococcal vaccine is
better [34,35], but the seroprotective rate 2 months after vaccina-
tion is still lower in IBD patients using anti-TNFa (86.6%) than in
those patients on non-immunosuppressive drugs (95.5%) [34].
Several studies report insufficient levels of Pertussis antibodies in
adults [36e38]. But a more recent study showed that the rate of
children and adolescents (11e18 years old) with combined immu-
nosuppressionwho reached adequate booster response to Pertussis
vaccination was 90% and comparable to healthy controls [39].
There have been some studies on vaccination response in in-
fants exposed to anti-TNFa in utero (Table 1), but most studies
measured vaccine response cross sectionally at different ages,
which makes interpretation of results difficult [14,40e45]. In some
of these reported children inadequate response to vaccination was
found, but numbers were too small to draw any conclusions. In a
retrospective study of 25 children, older than 12 months (14e70
months), who were exposed to infliximab or adalimumab in utero
the response on vaccinations for S. Pneumoniae, mumps, measles,
rubella and diphtheria were normal in all 15 children measured.
Serological response to H Influenzae was detectable in all children,
but levels were below protective value in 6 of 17 children. Hypo-
gammaglobulinemia was also found in 7 of 17 children (41%) [46].
In a recent larger study from the same research group, including
these previous results, serological response to vaccination to H
Influenzae was found to be inadequate in 17 out of 49 (34.7%)
exposed children at a mean age of 34 months [44]. Moreover 9 out
of 37 children (24.3%) had inadequate response to Mumps
measured at age 38.9 months. Interestingly though inadequate
responses to H Influenzae and Mumps were also found in the
control group. Response to other vaccination including Strepto-
coccus Pneumoniae, tetanus, diphtheria, measles and rubella were
considered normal. Interpretation of these data is difficult: mea-
surement of vaccination response should ideally be performed one
month after vaccination [47] and in these children, responses were
performed almost two years after primary vaccination.
Another study compared vaccination response for H Influenzae
and tetanus between 42 children exposed to biologicals and 8
children exposed to either other immunosuppressive drugs or no
immunosuppressive drugs. No significant differences were found,
but overall response rates were lower than historically reportedcals and JAK inhibitors during pregnancy on health-related outcomes
ice & Research Clinical Gastroenterology, https://doi.org/10.1016/
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6/15 inadequate response to Hib vaccine
15/15 adequate response to Streptococcus
Pneumoniae, mumps, measles, rubella and
diphtheria vaccines
4/25 serious infections requiring
hospitalisation
17/17 T en B cel-subsets normal
7/17 mild hypogamma-globulinemia (IgA
and/or IgG)
25/25 normal growth
1/25 mild psychomotor developmental delay
Beaulieu 2017 [45]
Prospective multicentre cohort
study, sub-study of the Pregnancy
















27/38 adequate response to Hib vaccine
33/41 adequate response to tetanus vaccine
Response to Hib and tetanus comparable to 8
controls (maternal IBD not exposed to anti- TNFa;




cohort study, including children of
the previous published study by












17/49 inadequate response to Hib vaccine (also
inadequate in 14/16 controls)
9/37 inadequate response to mumps vaccine (also
inadequate in 3/13 controls)
Adequate response to Streptococcus Pneumoniae
(45/46), tetanus (47/49), diphtheria (48/49),
measles (36/37) and rubella (36/37) vaccines
No increased risk of infections, use of
antibiotics or allergies
Growth and psychomotor development
similar to controls
De Lima 2018 [48]






12 months 15/15 response to hepatitis B vaccine adequate Growth, number of infections treated with
antibiotics, chronic diseases, allergies,
eczema comparable to controls (maternal
IBD not exposed to anti- TNFa)
Mahadevan 2006 [41]
Prospective cohort study, data from






7/8 adequate response to Hib vaccine
8/8 adequate response to tetanus vaccine
6/8 normal IgG, IgA; 4/6 low IgM
Sheibani 2016 [43]









11/12 adequate response to tetanus vaccine
11/12 adequate response to Hib vaccine
5/10 low IgM, 10/10 normal IgG and IgA
No serious infections
Vasiliauskas 2006 [40] casereport Infliximab
(n ¼ 1)
6 months adequate response to Hib, Streptococcus Pneumonia
and tetanus vaccine
Normal T en B cel-subsets, IgG, IgA, IgM and
in vitro lymphoproliferative responses to
non-specific mitogens
Normal growth and development, no





6 months 2/2 adequate response to Hib and Streptococcus
Pneumonia vaccines
Normal development and no infections
during follow up 4e11 months
J.W. Wieringa, C.J. van der Woude / Best Practice & Research Clinical Gastroenterology xxx (xxxx) xxx 3[45]. A study on the effectiveness of hepatitis B vaccination in
children born to IBD mothers did not observe a difference between
response to hepatitis B vaccination in 15 children exposed to anti
TNFa compared to 12 children not exposed to anti TNFa [48].Risk of infections after exposure to anti- TNFa therapy
A higher rate of infections in children exposed to the combi-
nation of anti-TNFa and thiopurines in utero was found in a pro-
spective study in 80 children. Children were compared to children
exposed to anti TNFamonotherapy, but not to an unexposed group
[16]. Larger andmore recent studies though seem reassuring on the
rate of infections, at least on the rate of infections requiring hos-
pitalisation of children exposed to anti-TNFa.
In a cohort of 53 children, who were exposed to anti TNFa in
utero and of whom data were retrospectively collected by using
questionnaires, the rate of infections was comparable to non-
exposed children during the first year of life. These children,
however, were advised not to attend normal day care [9]. A larger
European retrospective observational study, also using question-
naires, found an incidence rate of serious infections, requiringPlease cite this article as: Wieringa JW, van der Woude CJ, Effect of biologi
in children of women with inflammatory bowel disease, Best Pract
j.bpg.2019.101665hospitalisation of 2.8% per person in 388 children exposed to anti
TNFa with (n ¼ 99) or without (n ¼ 289) thiopurines. This was
comparable to children of womenwith IBD, unexposed to anti TNFa
or thiopurines [49]. But the majority of children (62%) were not
exposed during the third trimester and data considering anti TNFa
concentration in cord blood or children were lacking. None of
mentioned studies provide information about the occurrence of
mild infections.
A retrospective cohort study using data from the French national
health system database identified 799 children born to mothers
using anti-TNFa during pregnancy because of IBD [50]. Compared
to non-exposed children the anti-TNFa exposed children were
more often born prematurely and preterm birth was associated to a
higher risk of in-hospital infections. The overall rate of infections
(community acquired and in-hospital) was 43.7% and comparable
to the non-exposed group. Using a medico-administrative database
however cannot exclude some bias: recurrent less severe infections
not needing direct medical care will not be reported in these da-
tabases but could imply subtle influences on the developing im-
mune system.
Another retrospective cohort study using a medico-cals and JAK inhibitors during pregnancy on health-related outcomes
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mothers using anti-TNFa because of an auto-immune disease [51].
Fifty percent of mothers were diagnosed with IBD. The occurrence
of serious infections requiring hospitalisation in these children
ranged from 0 to 7% depending on concomitant exposure to other
immunosuppressive drugs during pregnancy, but statistical anal-
ysis did not show an association between anti-TNFa exposure and
serious infections in the first year of life.
Although the rate of infections, requiring hospitalisation are
reassuring the fact that these data are generated in a population
with high vaccination coverage should be taken into account. In the
Netherlands vaccination rates are dropping and this might impose
more risk in future.Auto immune disease and malignancies
Theoretically transplacental exposure to anti-TNFa might affect
anti-tumor surveillance as TNFa amongst others regulates cell
proliferation, differentiation, survival and apoptosis [52]. IBD pa-
tients treated with anti-TNFa inhibitors in combination with thio-
purines seem to have an increased risk of developing lymphoma
[53e56].
Currently no increase in neoplasms has been observed in chil-
dren exposed to anti-TNFa during pregnancy, although the length
of follow up is limited [49].
The development of autoimmune diseases such as TNFa
agonist-induced lupus-like syndrome (TAILS) might be another
concern might be. This has not been reported in children after
intra-uterine exposure to our knowledge. The incidence of allergies
does not seem to be increased compared to the general population
[46,48,49].Anti-integrins: vedolizumab
Vedolizumab is an anti-a4b7 integrin IgG1 monoclonal anti-
body, selectively modulating trafficking of memory B cells to the
inflamed gut. Vedolizumab targets the interaction between anti-
a4b7 and mucosal vascular adressin cell adhesion molecule 1
(MAdCAM), which is expressed in the gut, but is also expressed by
maternal vessels in the placenta [57]. In animal models the
importance of integrins during placentation and embryogenesis
has been shown [58]. Mutations in the a4 subunit gene in mice
cause dysfunctional placentation and consequently to the death of
the embryo [59].
Data on vedolizumb during pregnancy are limited. As with other
IgG1 antibodies vedolizumab placental transfer is expected, espe-
cially during the third trimester. Vedolizumab has a longer half-life
than adalimumab or infliximab and would theoretically result in
significant concentrations in the neonate, even if vedolizumab
would be discontinued in the third trimester [60,61]. But in the
Pregnancy in the Inflammatory Bowel Disease and Neonatal
Outcome (PIANO) registry the serum level in the exposed child at
birth was half of serum level of the mother [62]. Another small
report of two pregnant women with IBD also showed lower
vedolizumab cord blood levels than maternal levels at birth [63].
Last infusion of vedolizumab in these women had been at 10 and 5
weeks before birth. A low detectable level of vedolizumab was
found in one of two children at 6 months of age. In a recent pro-
spective cohort study of 21 pregnant women, spontaneous abortion
seemed more frequent in women treated with vedolizumab as
compared to anti TNFa or conventional treatment for IBD [64]. The
authors suggest that more severe and refractory IBD could be a
confounder and explanation for this finding, but larger studies are
needed to draw any conclusions.Please cite this article as: Wieringa JW, van der Woude CJ, Effect of biologi
in children of women with inflammatory bowel disease, Best Pract
j.bpg.2019.101665Risk of congenital malformations and unfavourable neonatal
pregnancy outcome
Theoretically blocking integrin function during pregnancy could
impose a higher risk for spontaneous abortion or congenital mal-
formations [58].
A report of the outcome of 24 unplanned pregnancies inwomen
treated with vedolizumab in 6 different clinical trials showed 5
elective abortions, 4 spontaneous abortions and 11 live births.
Congenital malformation (corpus callosum agenesis and left frontal
polymicrogyria) occurred in one child. Two births were premature.
Post marketing safety data of an additional 81 pregnancies in
women recorded 4 live births and 11 spontaneous abortions. Data
of the other 66 pregnancy outcomes were missing [65].
Recently a Belgian multicentre retrospective cohort study,
including 24 pregnancies in 24 women with IBD using vedolizu-
mab, reported 2 spontaneous abortions/still births and 23 life births
[66].Two patients continued vedolizumab throughout pregnancy
because of persistently active IBD. Four children were born pre-
mature and one (part of a twin) was small for gestational age.
Congenital malformations occurred in 3 children (hip dysplasia,
congenital pulmonary valve stenosis and Hirschsprung disease).
Vedolizumab and the developing immune system
To date no data are available concerning immunological devel-
opment in children exposed to vedolizumab during pregnancy.
Animal studies in pregnant cynomolgus monkeys receiving 10 mg/
kg (expected maximum human dose) or 100 mg/kg (10-fold ex-
pected human dose) vedolizumab every 2 weeks, showed no
changes in white blood cell counts and differentiation at 28 days,
120 days and 6 months after birth.
Vaccination of children after exposure to vedolizumab
Data on vaccination response in exposed children is limited. In a
study of 54 adults treated with vedolizumab the response to hep-
atitis B vaccinationwas comparable to placebo. The response to oral
cholera vaccination however was reduced, probably reflecting the
gut selective mechanism of action of vedolizumab [67]. In the
previous mentioned Belgian study no adverse events after vacci-
nation (including live attenuated rotavirus in 9 children) were
observed in 20 exposed children [66]. Beaulieu et al. included one
child exposed to vedolizumab in their previousmentioned study on
response to vaccination after intra uterine exposure to biologicals
[45].
Risk of infections after exposure to vedolizumab
Data concerning the risk of infection in children who were
exposed during pregnancy are scarce. Given the working mecha-
nism of vedolizumab an increased rate of (gastro-intestinal) in-
fections might be expected in exposed children. Safety data in
patients with IBD using vedolizumab show no increased risk of
infection [68]. In a small prospective study in 21 children treated
with vedolizumab respiratory tract infections were the most
frequent occurring infections and occurred 5 times during the
follow up period of 22 weeks after initiation of vedolizumab [69]. In
the Belgian study 1 of 23 children exposed during pregnancy, was
admitted to hospital during the first year of life because of fever of
unknown origin [66].
Autoimmune disease and malignancies
During follow up of 23 exposed children no malignancies havecals and JAK inhibitors during pregnancy on health-related outcomes
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23 weeks [66]. The risk of malignancies does not seem to be
increased in patients treated with vedolizumab either [68].
Anti IL12/23: ustekinumab
Ustekinumab is a monoclonal IgG1 antibody that prevents
interleukine-12 (IL-12) and interleukine-23 (IL-23) to interact with
their receptors on immune cells through binding to the p40 sub-
unit, which is present in both interleukines. IL12 and IL23 play an
important role in inflammatory diseases, including psoriasis and
IBD [70], but might also play a role in uterine physiology and
establishing pregnancy [71]. Ustekinumab is actively transported
cross the placenta, especially in the third trimester. Concentrations
of ustekinumab in cord blood were higher than maternal serum
levels, similar to anti-TNFa [62,72]. In a recent case report of one
pregnant women, who continued ustekinumab until 8 weeks
before delivery, the cord blood level was almost ten-times higher
than the maternal trough level directly after birth [73].
Risk of congenital malformations and unfavourable neonatal
pregnancy outcome
No increased risk of spontaneous abortions or congenital mal-
formations was seen in 65 pregnant women, exposed to at least one
dose of ustekinumab (most of them treated for psoriasis, 3 women
with IBD) [70,74].
Ustekinumab and the developing immune system
Immunological studies in infants after intra uterine exposure
have not been performed. Animal studies in pregnant macaques,
using high doses of ustekinumab showed no adverse effects on
their offspring. Immunophenotyping, immunohistopathology of
lymphoid tissues and T-dependent antibody responses were
normal [75].
Vaccination of children after exposure to ustekinumab
There are no data on vaccination response in children exposed
to ustekinumab during pregnancy, but data in adult patients
treated with ustekinumab seem reassuring.
In 60 adults treated because of psoriasis, response to 23-valent
pneumococcal vaccine and tetanus toxoid was adequate in 96.6%
and 84.7% of respectively [76]. This was comparable to control
psoriasis patients not receiving systemic treatment. Recently a
another study showed that response rate to hepatitis B vaccination
was higher in patients using ustekinumab as compared to patients
using infliximab or adalimumab [77].
Risk of infections after exposure to ustekinumab
Data of patients treatedwith ustekinumab because of IBD do not
showan increased risk for serious infections [70]. To our knowledge
there are however no data available about the risk of infection in
children exposed in utero.
Autoimmune disease and malignancies
The risk of autoimmune disease and malignancies after intra
uterine exposure is unknown. No increased risk of the occurrence
of malignancies has been reported in patients treated with uste-
kinumab [70].Please cite this article as: Wieringa JW, van der Woude CJ, Effect of biologi
in children of women with inflammatory bowel disease, Best Pract
j.bpg.2019.101665JAK inhibitors: tofacitinib
Tofacitinib is an oral inhibitor of the Janus kinase (JAK) family of
kinases, including JAK1 and JAK3. Through inhibition of JAK1 and
JAK3 tofacitinib inhibits signal transduction of several interleukins
and interferon, resulting in immunomodulation [78]. Recently the
European Medicines Agency (EMA) has recommended not to pre-
scribe tofacitinib in patients who are at risk of pulmonary throm-
boembolism as a higher risk of pulmonary thromboembolism has
been described in patients with RA using tofacitinib 10 mg twice
daily [79].
Studies on transplacental transport are lacking but given the
small size of tofacitinib, it is considered reasonable that tofacitinib
will be able to cross the placenta [80,81].
Congenital malformations and unfavourable neonatal pregnancy
outcome
Animal studies have shown tofacitinib to be teratogenic in
rabbits and in rats using dosages 13 to 146 times the recommended
dose of 5 mg twice daily [82]. Amongst others ventricular septal
defects, skeletal malformations and reduced foetal weight were
described. For this reason the current EMA recommendation is that
tofacitinib is contraindicated during pregnancy [79]. Outcomes of
tofacitinib safety databases of ulcerative colitis were recently re-
ported and combined with previously reported data from safety
databases for rheumatoid arthritis and psoriasis [80,81]. A total of
74 maternal exposed pregnancies were described of which 37
resulted in healthy new-borns. Congenital malformation (pulmo-
nary valve stenosis) was described in 1 neonate. Spontaneous
abortion occurred in 12 pregnancies, 13 pregnancies were termi-
nated for medical reasons and in 11 pregnancies outcome was
pending or mother was lost to follow up. In addition, amongst 42
maternal exposed pregnancies from non-interventional studies or
spontaneous adverse events reporting, 7 healthy new-borns,1 child
with a malformation (ventricular septum defect), 3 spontaneous
abortions, 1 medical terminations and 33 cases pending or lost to
follow up were described [80]. The risk for malformations or
spontaneous abortions seemed consistent with background risk in
the general population.
Tofacitinib and the developing immune system
To our knowledge there are no data on the development of the
immune system in children exposed in utero to tofacitinib. Neu-
tropenia has been described in adult patients treated with tofaci-
tinib [83].
Vaccination after exposure to tofacitinib
There are no reports on vaccination response in children
exposed during pregnancy, but concernsmight be raisedwhen data
on exposed adults are taken into account. In 102 adult patients
using tofacitinib for rheumatoid arthritis (RA) vaccination response
after polysaccharide pneumococcal vaccine was decreased
compared to placebo, whereas response to influenzae vaccine was
comparable [84]. Satisfactory response to vaccination, defined as a
twofold or more rise against 6 or more of 12 pneumococcal sero-
types, was achieved in 45.1% of patients on tofacitinib versus 68.4%
of RA patients receiving placebo. In another study amongst 60 adult
psoriasis patients using tofacitinib more than 80% of patients had
measurable titers to each serotype after 13-valent pneumococcal
conjugate vaccination and fourfold rise of tetanus toxoid was seen
in 60% of patients [85].cals and JAK inhibitors during pregnancy on health-related outcomes
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In a systematic review and meta-analysis on the efficacy and
safety of oral JAK inhibitors in adults with IBD the rate of infections
was found to be increased as compared to placebo, particularly for
herpes zoster [86]. There no data on the rates of infections after
exposure in utero.
Autoimmune disease and malignancies
The risk of malignancies or auto immune diseases has not yet
been studies in children exposed to oral JAK inhibitors during
pregnancy. In adults treated with oral JAK inhibitors the risk for
malignancies does not seem to be increased, but most studies are
relatively small and follow up was short [86].
Summarizing data and implications for care of exposed
children
Maintaining disease remission during pregnancy in women
with IBD is important to secure a healthy outcome of pregnancy for
both mother and child. Current guidelines therefore advise to
maintain IBD medication, including biologicals during pregnancy.
Recent data in children exposed to anti TNFa during pregnancy
seem reassuring as far as congenital malformations and serious
infections requiring hospital admission are concerned. Effects on
the developing immune system however cannot be excluded: one
infant died after BCG vaccination and some cases of neutropenia
with skin infections needing G-CSF have been reported. Moreover,
small studies have shown subtle changes in T and B cell subsets,
decreased response after mycobacterial challenge and vaccine
response rates lower than historically reported. Furthermore, the
reassuring data on infection rates are only in infections requiring
hospitalisation and are generated in a population with high vacci-
nation coverage. In the Netherlands vaccination rates are dropping
and this might impose more risk in future. Any firm conclusions at
this stage are impossible given the small size and retrospective
design of most studies.
Parents-to-be should be informed about the limited knowledge
on long term effects of exposure to biologicals and JAK inhibitors in
utero, the importance of administration of inactivated vaccines and
the fact that live-attenuated vaccines should be withheld until bi-
ologicals are no longer detectable in their child. Given the limited
data on long term effects follow up of children exposed to bi-
ologicals seemswarranted.Wewould suggest measuring drug level
at birth and to check for neutropenia in cord blood. The functional
capacity of the immune system can be evaluated by measuring
response to routinely administered inactivated vaccines during the
first months of life. If an adequate response is lacking, adminis-
trating a booster vaccine might be considered. Follow up in a pro-
spective study design to evaluate the necessity of immunological
follow up is suggested.
Practice points
 Relapse of IBD during pregnancy is associated with unfav-
ourable pregnancy outcome. Therefore, current guidelines
advise to maintain immunosuppressive drugs during
pregnancy.
 The risk of congenital malformation and serious infections
requiring hospital admission does not seem to be increased in
children exposed to anti TNFa during pregnancy, but the effect
on the developing immune system is uncertain. Safety data on
children exposed to vedolizumab, ustekinumab and tofacitinib
are limited and conclusions on the use of these drugs cannot be
drawn.Please cite this article as: Wieringa JW, van der Woude CJ, Effect of biologi
in children of women with inflammatory bowel disease, Best Pract
j.bpg.2019.101665 Administration of live attenuated vaccines should be withheld
as long as the biologicals or JAK inhibitor is still detectable.
Research agenda
 Follow up of children exposed to biologicals during pregnancy
in a prospective study design is necessary to evaluate both short
term and long-term effects on the developing immune system.
 New biologicals, JAK inhibitors or other first in-class drugs with
immune suppressive action require extensive evaluation in
pregnancy including placental transfer, drug levels at birth and
health-related outcome in new-borns.
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